Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPE | Q05469 | 9/20 | 0.53 |
| ▸ | BCHE | P06276 | 1/20 | 0.53 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.48 |
| ▸ | CCR2 | P41597 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.46 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5648723 | 0.94 | LIPE (0.55) | LIPEBCHECCR2KCNH2NPC1 | |
| SCHEMBL5647329 | 0.84 | FAAH (0.61) | LIPEBCHESMN1; SMN2TRPA1 | |
| SCHEMBL5648074 | 0.83 | LIPE (0.48) | LIPEBCHECCR2KCNH2NPC1 | |
| SCHEMBL5647711 | 0.83 | LIPE (0.58) | LIPEBCHENPC1MAPTHTT | |
| SCHEMBL5649451 | 0.83 | LIPE (0.58) | LIPEBCHENPC1MAPTHTT | |
| SCHEMBL5650600 | 0.82 | LIPE (0.75) | LIPEBCHEKCNH2MAPTHTT | |
| SCHEMBL5650677 | 0.82 | LIPE (0.73) | LIPEBCHENPC1MAPTHTT | |
| SCHEMBL5651171 | 0.81 | LIPE (0.73) | LIPEBCHEKCNH2MAPTHTT | |
| SCHEMBL5649257 | 0.79 | LIPE (0.71) | LIPEBCHEMAPTHTTSMN1; SMN2 | |
| SCHEMBL5647381 | 0.78 | LIPE (0.72) | LIPEBCHEKCNH2MAPTHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060160820-A1 | Substituted piperazine carbamates | NOVO NORDISK A/S (DK) | 2006-07-20 | — | — | US | claimed |
| EP-1458374-A2 | COMPOUNDS AND USES THEREOF FOR DECREASING ACTIVITY OF HORMONE-SENSITIVE LIPASE | NOVO NORDISK A/S (DK) | 2004-09-22 | — | — | EP | claimed |
| US-20030166644-A1 | Compounds and uses thereof for decreasing activity of hormone-sensitive lipase | NOVO NORDISK A/S (DK) | 2003-09-04 | — | — | US | claimed |
| WO-2003051841-A2 | COMPOUNDS AND USES THEREOF FOR DECREASING ACTIVITY OF HORMONE-SENSITIVE LIPASE | NOVO NORDISK A/S (DK) | 2003-06-26 | — | — | WO | claimed |
| US-7279470-B2 | Compounds and uses thereof for decreasing activity of hormone-sensitive lipase | NOVO NORDISK A/S (DK) | 2007-10-09 | — | — | US | disclosed |
| US-7067517-B2 | Use of compounds for decreasing activity of hormone-sensitive lipase | NERO NORDISK A/S (DK) | 2006-06-27 | — | — | US | disclosed |
| EP-1458375-A2 | COMPOSITIONS FOR DECREASING ACTIVITY OF HORMONE-SENSITIVE LIPASE | NOVO NORDISK A/S (DK) | 2004-09-22 | — | — | EP | disclosed |
| EP-1458374-A2 | COMPOUNDS AND USES THEREOF FOR DECREASING ACTIVITY OF HORMONE-SENSITIVE LIPASE | NOVO NORDISK A/S (DK) | 2004-09-22 | — | — | EP | disclosed |
| US-20030166644-A1 | Compounds and uses thereof for decreasing activity of hormone-sensitive lipase | NOVO NORDISK A/S (DK) | 2003-09-04 | — | — | US | disclosed |
| US-20030166690-A1 | Use of compounds for decreasing activity of hormone-sensitive | NOVO NORDISK A/S (DK) | 2003-09-04 | — | — | US | disclosed |
| WO-2003051841-A2 | COMPOUNDS AND USES THEREOF FOR DECREASING ACTIVITY OF HORMONE-SENSITIVE LIPASE | NOVO NORDISK A/S (DK) | 2003-06-26 | — | — | WO | disclosed |
| WO-2003051842-A2 | COMPOSITIONS DECREASING ACTIVITY OF HORMONE-SENSITIVE LIPASE | NOVO NORDISK A/S (DK) | 2003-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030166644-A1 | Compounds and uses thereof for decreasing activity of hormone-sensitive lipase | LIPE, PNLIP, LPL | LIPE 1/4885BCHE 126/4885S1PR2 3237/4885 |
| US-20030166690-A1 | Use of compounds for decreasing activity of hormone-sensitive | LIPE, PNLIP, LPL | LIPE 1/4885BCHE 112/4885S1PR2 3505/4885 |
| US-20060160820-A1 | Substituted piperazine carbamates | LIPE, PNLIP, LPL | LIPE 1/4885BCHE 47/4885S1PR2 2637/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.